This week we have received wonderful news!
There will be another line of therapy for GIST patients now that NICE has produced final draft guidance recommending Ripretinib (Qinlock) for ‘the treatment of adult GIST patients who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ripretinib is much better tolerated than earlier lines of therapy.
It has been a long two-year journey to gain this drug approval for patients in England and Wales. We extend our thanks and gratitude to all of the GIST specialists, Patients, Carers and Advocacy representatives, whose knowledge and first-hand experience helped to make his recommendation possible.
